托法替布的安全性分析及中国人群数据.pptVIP

Speaker Notes: This slide shows the 2016 incidence rates for all malignancies excluding NMSC, as well as specific incidence rates for NMSC, lung, breast, lymphoma, and melanoma As of January 2016 in the pooled LTE studies, 58 malignancies were reported in 1525 patients for 托法替布(托法替布 citrate) 5 mg twice daily (incidence rate of 1.03 per 100 患者年)1 In the 7 controlled clinical trials, 11 solid cancers and 1 lymphoma were diagnosed in 3328 patients receiving 托法替布with or without a DMARD. This compares with 0 solid cancers and 0 lymphomas in 809 patients in the 安慰剂 with or without DMARD group during